Pacific Biosciences PACB

$2.54 +0.03 (1.20%)

Valuation

Market cap
780,186,000
Revenue TTM
$160,010,000
Net income TTM
$-546,380,000
PE ratio
0.00
Forward PE
—
Profit margin
-341.47%
Debt to equity
0.00

Trading

Volume
26,011,199
Avg volume
9,684,594
Day's range
$2.44 – $2.64
Shares out
310,831,000
Stochastic %K
92%
Beta
2.19
Analysts
Sell
Price target
$2.17

Price

Company profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library forma...

Show more

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Industry
Medical Devices
Sector
Healthcare
Phone
650 521 8000
Website
https://www.pacb.com
Address
1305 O’Brien Drive, Menlo Park, United States

Latest news

Stocktwits

Razor_Ramon Oct 3, 8:33 PM
$PACB This janitor thinks he's a physician. Proof you can be whomever you want to be on the internet.
0 replies
Guadangia Oct 3, 5:56 PM
$PACB If you are short at 2,6 then definitely PACB will blow up the big 2,7s wall
0 replies
Yooman Oct 3, 10:57 AM
$PACB On the August 26 you wrote this: "I took a short today in this over-hyped stock at 1.58$. Future genomic dreams do not matter. " You must be a real expert. No further comment is necessary.
1 replies
Razor_Ramon Oct 3, 5:19 AM
$PACB i think ILMN is shaking in their corporate shoes
0 replies
Razor_Ramon Oct 3, 5:04 AM
$PACB Razor is all discombobulated Waking up from Haku Did we gain esses?
0 replies
MingLin Oct 3, 4:57 AM
$PACB Racism 👍🏽🇨🇳 Pacbio is super good. Definite try for save world. No scam for see here
0 replies
BioGem Oct 3, 4:51 AM
$PACB Started a short near $2.6 and will add more if higher on the fluff pump (future dreams and rainbows). Huge bubble to swiftly plummet at the Q3 financial report: -Revenue guidance has been drastically reduced. Growth rate is zero, competition is ruthless, and adoption in the ditch. -Net loss of -45M per quarter = will never ever be profitable. -Cash burn of -40M every single quarter = cash evaporates in 2027. -Hefty debt of 650M to be refinanced at much higher rates = risk of BK. -Hefty dilution every single quarter of the outstanding shares. -No prestigious bio funds are invested. -High short interest = consensus of poor stock. -Last analyst has price target of $1.35.
1 replies
DylanGFM Oct 3, 4:50 AM 1 replies